BioSpace News Archive

Vast’s Second Drug Candidate achieves 99% reduction of NTM

4G Clinical Selected for its Utilization of Natural Language Processing to Turn Study Parameters into Detailed Forecasts

Using large data sets & machine learning across biomarkers, innovative tech can speed time to detection, intervention & treatment, while improving outcomes & reducing spread of disease

Five physicians chosen to receive movement disorders clinical and research training at top-tier international academic centers

The agreement creates a partnership in which OWP blends the ancestral techniques of the Nasa people with modern technology, registered plant genetics and international standard operating procedures.

Patients living in Quebec will now have access, through the Régie de l’assurance maladie Québec (RAMQ), to DUPIXENT™ (dupilumab).1 DUPIXENT™ is used to treat adult patients with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable

Honorees recognized for groundbreaking efforts to accelerate scientific progress toward new treatments for neurodegenerative diseases

Medical Marijuana, Inc. (“the Company”) (OTC: MJNA), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary Kannaway® has been selected as a member of the Board of Directors for the U.S. Hemp Roundtable.

The software company is commencing its pivotal multi-center clinical trial, aimed at demonstrating the efficacy of its ground-breaking product - AutocathFFR

Neurelis’ investigational product candidate, VALTOCO® (diazepam nasal spray), currently under review by the U.S. Food and Drug Administration